Clinical trial NCT00515203: Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Official title: A Randomized, Double-Blind, Placebo-controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Pediatric Subjects With Chronic Immune (Idiopathic) Thrombocytopenic Purpura
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Idiopathic Thrombocytopenic Purpura
Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Keywords: Immune (Idiopathic) Thrombocytopenic Purpura
Pediatric Idiopathic Thrombocytopenic Purpura
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2007-08-13
Enrollment: 22
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an effective dose and schedule, will be well tolerated treatment for thrombocytopenia among pediatric subjects with chronic ITP.


Eligibility criteria: Inclusion Criteria:

* Before any study-specific procedure, the appropriate written informed consent must be obtained. In addition to the written informed consent, the assent of the child from those subjects capable of providing assent must also be obtained if requested by the IRB/IEC.
* Diagnosis of ITP according to The American Society of Hematology (ASH) Guidelines at least six months prior to screening
* Age ≥ 12 months and \< 18 years at enrollment
* The mean of two platelet counts taken during the screening period must be ≤ 30 x 10\^9/L with no single count \>35 x 10\^9/L
* A serum creatinine concentration ≤ 1.5 times the laboratory normal range (for each age category)
* Adequate liver function; serum bilirubin ≤ 1.5 times the laboratory normal range
* Hemoglobin \>10.0 g/dL

Exclusion Criteria:

* Known history of a bone marrow stem cell disorder (any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study)
* Known history of venous or arterial thrombotic or thromboembolic event
* Known history of congenital thrombocytopenia
* Known history of malignancy except basal cell carcinoma
* Known history of hepatitis B, hepatitis C, or HIV
* Known history of systemic lupus erythematosus, Evans Syndrome, or autoimmune neutropenia
* Known positive lupus anticoagulant or history of antiphospholipid antibody syndrome
* Known history of Disseminated Intravascular Coagulation, Hemolytic Uremic Syndrome, or Thrombotic Thrombocytopenic Purpura
* Currently receiving any treatment for ITP except for corticosteroids
* IV Ig or anti-D Ig within two weeks prior to the screening visit
* Rituximab (for any indication) within 14 weeks before the screening visit or anticipated use during the time of the proposed study
* Splenectomy within eight weeks of the screening visit
* Received hematopoietic growth factors including IL-11 (oprelvekin) within four weeks before the screening visit
* Received any alkylating agents within eight weeks before the screening visit or anticipated use during the time of the proposed study
* Subject is currently enrolled in or has not yet completed at least four weeks since ending other investigational device or drug trial(s), or subject is receiving investigational agent(s)
* Past or present participation in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), AMG 531, or related platelet product
* Pregnant (i.e. positive urine pregnancy test) or breast feeding
* Subject is not using adequate contraceptive precautions, if applicable.
* Known hypersensitivity to any recombinant E coli-derived product
* Subject has any kind of disorder that compromises the ability to comply with all study procedures

Primary outcomes:
measure: Adverse Events
timeFrame: 12 weeks
Secondary outcomes:
measure: Weeks With Platelet Count ≥ 50 x 10^9/L
timeFrame: 12-week treatment period
measure: Bleeding Events (Grade 2 or Higher)
timeFrame: 12-week treatment period (Weeks 2 - 13)
measure: Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks
timeFrame: 12-week treatment period
measure: Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks
timeFrame: 12-week treatment period
measure: Requirement for Rescue Therapy (as Defined Per Protocol)
timeFrame: 12-week treatment period
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
citation: Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908. Epub 2011 Apr 18.
citation: Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012 Mar;58(3):395-8. doi: 10.1002/pbc.23312. Epub 2011 Sep 9.